A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Gynecologic Oncology

Volumn 134, Issue 3, 2014, Pages 478-485

  Penson, Richard T ^a   Moore, Kathleen M ^b   Fleming, Gini F ^c   Braly, Patricia ^d   Schimp, Veronica ^e   Nguyen, Hoa ^f   Matulonis, Ursula A ^g   Banerjee, Susana ^h   Haluska, Paul ⁱ   Gore, Martin ^j   Bodurka, Diane C ^k   Hozak, Rebecca R ^l   Joshi, Adarsh ^l   Xu, Yihuan ^l   Schwartz, Jonathan D ^l,n   McGuire, William P ^m  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d Hematology and Oncology Specialists LLC Harry T Howard II Memorial Infusion Center   (United States)

^e M D ANDERSON CANCER CENTER ORLANDO   (United States)

^f Gynecologic Oncology Associates Inc   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h Royal Marsden Hospital   (United Kingdom)

ⁱ MAYO CLINIC   (United States)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l ELI LILLY AND COMPANY   (United States)

^m INOVA FAIRFAX HOSPITAL   (United States)

ⁿ Stemline Therapeutics Inc   (United States)

more..

Author keywords

Angiogenesis; Antiangiogenic; Clear cell; Resistant; VEGF

Indexed keywords

CISPLATIN DERIVATIVE; GLYCAN; PHOSPHATIDYLINOSITOL; RAMUCIRUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMATOUS PERITONITIS; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GINGIVA BLEEDING; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; INSOMNIA; INTESTINE PERFORATION; LIMB PAIN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; OVARY CARCINOMA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; UTERINE TUBE CARCINOMA; VOMITING; WEIGHT REDUCTION; ADOLESCENT; ANGIOGENESIS; ANTIANGIOGENIC; CARCINOMA; CLEAR CELL; DISEASE FREE SURVIVAL; MORTALITY; OVARY TUMOR; PERITONEUM TUMOR; RESISTANT; SURVIVAL RATE; TUMOR RECURRENCE; UTERINE TUBE TUMOR; YOUNG ADULT;

ANGIOGENESIS; ANTIANGIOGENIC; CLEAR CELL; RESISTANT; VEGF;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84908344383     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.06.029     Document Type: Article

References (24)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J Clin, 2012, 63.
2. Claesson-Welsh, L., Welsh, M., VEGFA and tumour angiogenesis. J Intern Med 273 (2013), 114–127.
3. Subramanian, J., Morgensztern, D., Govindan, R., Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 11 (2010), 311–319.
4. Koolwijk, P., Peters, E., van der Vecht, B., Hornig, C., Weich, H.A., Alitalo, K., et al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 4 (2001), 53–60.
5. Meeson, A.P., Argilla, M., Ko, K., Witte, L., Lang, R.A., VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 126 (1999), 1407–1415.
6. Witte, L., Hicklin, D.J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17 (1998), 155–161.
7. Zhu, Z., Bohlen, P., Witte, L., Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2 (2002), 135–156.
8. Burger, R.A., Sill, M.W., Monk, B.J., Greer, B.E., Sorosky, J.I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007), 5165–5171.
9. Cannistra, S.A., Matulonis, U.A., Penson, R.T., Hambleton, J., Dupont, J., Mackey, H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 (2007), 5180–5186.
10. Spratlin, J.L., Cohen, R.B., Eadens, M., Gore, L., Camidge, D.R., Diab, S., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28 (2010), 780–787.
11. Chiorean, E., Sweeney, C., Hurwitz, H., Savage, S., Cohen, R., Schwartz, J., et al. Phase I dose-escalation study of the anti-VEGFR-1 recombinant human IgG1 MAb IMC-1121B administered every other weeks (q2W) or every 3 (q3w) in patients (pts) with advanced cancers. Molecular targets and cancer therapeutics Conference Proceedings Abstract, 2007, B2007.
12. Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278 (2003), 43496–43507.
13. Zhu, Z., Hattori, K., Zhang, H., Jimenez, X., Ludwig, D., Dias, S., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17 (2003), 604–611.
14. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
15. Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
16. Kerbel, R.S., Tumor angiogenesis. N Engl J Med 358 (2008), 2039–2049.
17. Gaitskell, K., Martinek, I., Bryant, A., Kehoe, S., Nicum, S., Morrison, J., Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev, 2011, CD007930.
18. Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
19. Herzog, T.J., Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 10 (2004), 7439–7449.
20. Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
21. Abdullah, S.E., Perez-Soler, R., Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 118 (2012), 3455–3467.
22. Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008), 592–603.
23. Moreno Garcia, V., Basu, B., Molife, L.R., Kaye, S.B., Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 18 (2012), 3750–3761.
24. Zand, B., Coleman, R.L., Sood, A.K., Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am 26 (2012), 543–563 [viii].